Science Foundation Arizona (SFAz) encourages Community College Hispanic Serving Institutions (HSIs) that meet eligibility requirements to apply for Cohort 3 of the KickStarter Program with support by National Science Foundation (NSF HRD# 1450061).
It is well-recognized that patients receiving carboplatin as second-line treatment of ovarian. cancer have at least a modest risk for experiencing hypersensitivity reactions.1 The onset of. reactions is unpredictable and they could occur immediately upon initiation of the drug infusion. or may not be seen until one half or more of the infusion has been administered to the patient. On the other hand, the onset of the reactions has also been reported in patients receiving more. than six cumulative courses. The symptoms associated with the reactions range from a minor. rash to diffuse erythroderma, pruritis, severe anxiety, dyspnea, tachycardia, hypotension, and in. severe cases, death.
Hyperbilirubinemia is a condition in which there is too much bilirubin in the blood. When red blood cells break down, a substance called bilirubin is formed.Babies are not easily able to get rid of the bilirubin and it can build up in the blood and other tissues and fluids of the baby's body.This is called hyperbilirubinemia. Because bilirubin has a pigment or coloring, it causes a yellowing of the baby's skin, eyes, and other tissues. This is called jaundice.Depending on the cause of the hyperbilirubinemia, jaundice may appear at birth or at any time afterward.ecause bilirubin has a pigment or coloring, it causes a yellowing of the baby's skin, eyes, and other tissues. This is called jaundice. Depending on the cause of the hyperbilirubinemia, jaundice may appear at birth or at any time afterward.